SUS CLINICALS INC

Cincinnati, OH · Founded 2020 · CIK 0002007598 · Biotech · Private

Software platform for identifying and prioritizing promising cancer therapeutic candidates

susclinicals.com →
Grants
$3.0M
3 awards
Sector median: 1
Raised
$3.5M
1 Form D · Jan 2024
33 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase II · Validation of the Genetically Malleable Oncopig Hepatocellular carcinoma (HCC) Model for Targeted Therapeutic Development$964,276
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase II · Validation of the Genetically Malleable Oncopig Hepatocellular carcinoma (HCC) Model for Targeted Therapeutic Development$964,276
Private capital raisedForm D · SEC$3,504,636
Federal grantDepartment of Health and Human Services · Phase II · Validation of the Genetically Malleable Oncopig Hepatocellular carcinoma (HCC) Model for Targeted Therapeutic Development$1,035,724
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2320ARUKA BIO, INC.—$3.6M
2321Genomics PLC——
2322Lennham Pharmaceuticals, Inc.—$3.5M
2323SUS CLINICALS INC—$3.5M
2324Myricx Bio——
2325Abiologics——
2326APT THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Stephen BaggottDirector · Executive Officer
  • Geoffrey MarshallDirector · Executive Officer
  • Jeffrey WeedmanDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.